期刊文献+

Is X-linked methyl-CpG binding protein 2 a new target for the treatment of Parkinson's disease? 被引量:1

Is X-linked methyl-CpG binding protein 2 a new target for the treatment of Parkinson’s disease?
下载PDF
导出
摘要 X-linked methyl-CpG binding protein 2 mutations can induce symptoms similar to those of Parkinson’s disease and dopamine metabolism disorders, but the specific role of X-linked methyl-CpG binding protein 2 in the pathogenesis of Parkinson’s disease remains unknown. In the present study, we used 6-hydroxydopamine-induced human neuroblastoma cell (SH-SY5Y cells) injury as a cell model of Parkinson’s disease. The 6-hydroxydopamine (50 μmol/L) treatment decreased protein levels for both X-linked methyl-CpG binding protein 2 and tyrosine hydroxylase in these cells, and led to cell death. However, overexpression of X-linked methyl-CpG binding protein 2 was able to ameliorate the effects of 6-hydroxydopamine, it reduced 6-hydroxydopamine-induced apoptosis, and increased the levels of tyrosine hydroxylase in SH-SY5Y cells. These findings suggesting that X-linked methyl-CpG binding protein 2 may be a potential therapeutic target for the treatment of Parkinson’s disease. X-linked methyl-CpG binding protein 2 mutations can induce symptoms similar to those of Parkinson’s disease and dopamine metabolism disorders, but the specific role of X-linked methyl-CpG binding protein 2 in the pathogenesis of Parkinson’s disease remains unknown. In the present study, we used 6-hydroxydopamine-induced human neuroblastoma cell (SH-SY5Y cells) injury as a cell model of Parkinson’s disease. The 6-hydroxydopamine (50 μmol/L) treatment decreased protein levels for both X-linked methyl-CpG binding protein 2 and tyrosine hydroxylase in these cells, and led to cell death. However, overexpression of X-linked methyl-CpG binding protein 2 was able to ameliorate the effects of 6-hydroxydopamine, it reduced 6-hydroxydopamine-induced apoptosis, and increased the levels of tyrosine hydroxylase in SH-SY5Y cells. These findings suggesting that X-linked methyl-CpG binding protein 2 may be a potential therapeutic target for the treatment of Parkinson’s disease.
出处 《Neural Regeneration Research》 SCIE CAS CSCD 2013年第21期1948-1957,共10页 中国神经再生研究(英文版)
基金 sponsored by the Ph.D.Independent Research Projects of Wuhan University,No.201130302020017 a grant from the Science and Technology Bureau of Hubei Province,No.2011CDB511 the National Natural Science Foundation of China,No.81170769
关键词 neural regeneration neurodegenerative diseases Parkinson’s disease methyl-CpG-binding protein 2 tyrosine hydroxylase 6-HYDROXYDOPAMINE dopaminergic neurons SH-SY5Y cells grants-supported paper NEUROREGENERATION neural regeneration neurodegenerative diseases Parkinson’s disease methyl-CpG-binding protein 2 tyrosine hydroxylase 6-hydroxydopamine dopaminergic neurons SH-SY5Y cells grants-supported paper neuroregeneration
  • 相关文献

参考文献61

  • 1Gasser T. Genetics of Parkinson's disease. J Neurol. 2001 ;248(1 0):833-840.
  • 2Fearnley JM, lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991 ;114(Pt 5):2283-2301.
  • 3Ossig C, Reichmann H. Treatment of Parkinson's disease in the advanced stage. J Neural Transm. 2013;120(4): 523-529.
  • 4Steece-Collier K, Maries E, Kordower JH. Etiology of Par?kinson's disease: Genetics and environment revisited. Proc Natl Acad Sci USA. 2002;99(22): 13972-13974.
  • 5Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci. 2004;27(9):561-568.
  • 6Kumar A, Sharma N, Gupta A, et al. Neuroprotective po?tential of atorvastatin and simvastatin (HMG-CoA reduc?tase inhibitors) against 6-hydroxydopamine (6-0HDA) induced Parkinson-like symptoms. Brain Res. 2012;1471: 13-22.
  • 7Yamamoto T, Nair P, Davi s P, et al. Design, synthesis, and biological evaluation of novel bifunctional C-terminal?modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists. J Med Chem. 2007; 50(12):2779-2786.
  • 8Chen Q, He Y, Yang K. Gene therapy for Parkinson's disease: progress and challenges. Curr Gene Ther. 2005;5(1 ):71-80.
  • 9Carlsson T, Bjorklund T, Kirik D. Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vec?tor-mediated enzyme replacement strategy. Curr Gene Ther. 2007;7(2):109-120.
  • 10Shen Y, Muramatsu SI, Ikeguchi K, et al. Triple transduc?tion with adeno-associated virus vectors expressing tyro?sine hydroxylase, aromatic-l-amino-acid decarboxylase, and GTP cyciohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther. 2000;11(11):1509-1519.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部